-
1
المؤلفون: Matthias G. Hautmann, Christian Rübe, Stefan Gräber, Patrick Melchior, Lara Natalie Müller, Jochen Fleckenstein, Yvonne Dzierma, Marcus Niewald
المصدر: Strahlentherapie und Onkologie. 198:370-377
مصطلحات موضوعية: Adult, medicine.medical_specialty, Randomization, Visual analogue scale, medicine.medical_treatment, Pain, Osteoarthritis, Placebo, Quality of life, Internal medicine, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Prospective Studies, business.industry, Low dose, Osteoarthritis, Knee, medicine.disease, Radiation therapy, Treatment Outcome, Oncology, Rheumatoid arthritis, Quality of Life, business, Follow-Up Studies
الوصف: Purpose Randomized comparison of the effect of radiotherapy on painful osteoarthritis (OA) applying a standard-dose vs. a very-low-dose regime Patients and methods Patients with OA of the hand and knee joints were included. Further inclusion criteria: symptoms for more than 3 months, favorable general health status, age above 40 years. Patients with prior local radiotherapy, trauma, rheumatoid arthritis, or vascular diseases were excluded. After randomization (every joint was randomized separately), the following protocols were applied: standard arm: total dose 3.0 Gy, single fractions of 0.5 Gy twice weekly; experimental arm: total dose 0.3 Gy, single fractions of 0.05 Gy twice weekly. The dosage was not known to the patients. The patients were examined 3 and 12 months after radiotherapy. Scores like VAS (visual analogue scale), KOOS-SF (the knee injugy and osteoarthritis outcome score), SF-SACRAH (short form score for the assessment and quantification of chronic rheumatic affections of the hands), and SF-12 (short form 12) were used. Results A total of 64 knees and 172 hands were randomized. 3.0 Gy was applied to 87 hands and 34 knees, 0.3 Gy was given to 85 hands and 30 knees. After 3 months, we observed good pain relief after 3 Gy and after 0.3 Gy, there was no statistically significant difference. Side effects were not recorded. The trial was closed prematurely due to slow recruitment. Conclusion We found favorable pain relief and a limited response in the functional and quality of life scores in both arms. The effect of low doses such as 0.3 Gy on pain is widely unknown. Further trials are necessary to compare a conventional dose to placebo and to further explore the effect of low doses on inflammatory disorders.
-
2
المؤلفون: Antoniu-Oreste Gostian, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Matthias G. Hautmann, Thomas B. Brunner, Simon Laban, Gunther Klautke, Balint Tamaskovics, Benjamin Frey, Arndt Hartmann, Wilfried Budach, Udo Gaipl, Heinrich Iro, Rainer Fietkau, Markus Hecht
المصدر: Abstract- und Posterband - 93. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn Interface - Fokus Mensch im Zeitalter der technisierten Medizin.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0f1c47676992acaf5b91dad8dff74643
https://doi.org/10.1055/s-0042-1747265 -
3
المؤلفون: Antoniu-Oreste Gostian, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Matthias G. Hautmann, Thomas B. Brunner, Simon Laban, Gunther Klautke, Balint Tamaskovics, Benjamin Frey, Arndt Hartmann, Wilfried Budach, Udo Gaipl, Heinrich Iro, Rainer Fietkau, Markus Hecht
المصدر: Abstract- und Posterband - 93. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn Interface - Fokus Mensch im Zeitalter der technisierten Medizin.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::700b1ac3fafea689da8ea37920426eb0
https://doi.org/10.1055/s-0042-1746637 -
4
المؤلفون: Markus Hecht, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Gunther Klautke, Simon Laban, Matthias G Hautmann, Thomas B Brunner, Bálint Tamaskovics, Axel Hinke, Jian-Guo Zhou, Benjamin Frey, Anna-Jasmina Donaubauer, Ina Becker, Sabine Semrau, Arndt Hartmann, Panagiotis Balermpas, Wilfried Budach, Udo S Gaipl, Heinrich Iro, Antoniu-Oreste Gostian, Rainer Fietkau
المصدر: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancerمصطلحات موضوعية: Male, Cancer Research, Immunology, CD8-Positive T-Lymphocytes, Radioimmuntherapie, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Immunology and Allergy, ddc:610, Immune Checkpoint Inhibitors, RC254-282, Aged, Clinical/Translational Cancer Immunotherapy, Pharmacology, Squamous Cell Carcinoma of Head and Neck, Patient Selection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Induction Chemotherapy, Middle Aged, Radioimmunotherapy, Oncology, Head and Neck Neoplasms, Molecular Medicine, Female, DDC 610 / Medicine & health
الوصف: PurposeThe first aim of the trial is to study feasibility of combined programmed death protein ligand 1/cytotoxic T-lymphocyte-associated protein 4 inhibition concomitant to radiotherapy. In addition, efficacy of the entire treatment scheme consisting of induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT) after intratumoral CD8 +immune cell-based patient selection will be analyzed.MethodsPatients with stage III–IVB head and neck squamous cell carcinoma were eligible for this multicenter phase II trial. Treatment consisted of a single cycle of cisplatin 30 mg/m² days 1–3, docetaxel 75 mg/m² day 1, durvalumab 1500 mg fix dose day 5 and tremelimumab 75 mg fix dose day 5. Patients with increased intratumoral CD8 +immune cell density or pathological complete response (pCR) in the rebiopsy entered RIT up to a total dose of 70 Gy. Patients received further three cycles of durvalumab/tremelimumab followed by eight cycles of durvalumab mono (every 4 weeks). The intended treatment for patients not meeting these criteria was standard radiochemotherapy outside the trial. Primary endpoint was a feasibility rate of patients entering RIT to receive treatment until at least cycle 6 of immunotherapy of ≥80%.ResultsBetween September 2018 and May 2020, 80 patients were enrolled (one excluded). Out of these, 23 patients had human papilloma virus (HPV)-positive oropharyngeal cancer. Median follow-up was 17.2 months. After induction chemoimmunotherapy 41 patients had pCR and 31 had increased intratumoral CD8 +immune cells. Of 60 patients entering RIT (primary endpoint cohort), 10 experienced imiting toxic (mainly hepatitis) and four discontinued for other reasons, resulting in a feasibility rate of 82%. The RIT cohort (n=60) had a progression-free survival (PFS) rate at one and 2 years of 78% and 72%, respectively, and an overall survival rate at one and 2 years of 90% and 84%, respectively. Patients with HPV-positive oropharyngeal cancers had greater benefit from RIT with a 2-year PFS rate of 94% compared with 64% for HPV-negative oropharyngeal cancers and other locations. In the entire study cohort (n=79) the 2-year PFS rate was 68% (91% for HPV-positive oropharynx vs 59% for others). Toxicity grade 3–4 mainly consisted of dysphagia (53%), leukopenia (52%) and infections (32%).ConclusionsThe trial met the primary endpoint feasibility of RIT. Induction chemo-immunotherapy followed by chemotherapy-free RIT after intratumoral CD8 +immune cell-based patient selection has promising PFS.Trial registration numberThe trial was registered with ClinicalTrials.gov (identifier: NCT03426657). The trial was conducted as investigator-sponsored trial (IST).
publishedVersionوصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9adc7c09d51657b2ad69ca9f824a87f
-
5
المؤلفون: Christoph Henkenberens, Martin Stuschke, Claus Belka, Daniel Martin, Bülent Polat, Panagiotis Balermpas, Christian Weiß, Guido Hildebrandt, Cihan Gani, Stephanie E. Combs, Thomas Brunner, Chiara Valentini, David Krug, Claus Rödel, Jürgen Debus, Matthias G. Hautmann, Thomas Kuhnt, Emmanouil Fokas, Ursula Nestle, Henning Schäfer, Tilman Bostel, Rita Engenhart-Cabillic, Johannes Gollrad
المساهمون: University of Zurich, Fokas, Emmanouil
المصدر: Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 23, Iss, Pp 43-49 (2020)مصطلحات موضوعية: Oncology, Durvalumab, DFS, disease-free survival, medicine.medical_treatment, R895-920, Medizin, RT, radiotherapy, PD-1, programmed death receptor 1, 030218 nuclear medicine & medical imaging, law.invention, Medical physics. Medical radiology. Nuclear medicine, 0302 clinical medicine, Randomized controlled trial, law, Disease, RC254-282, free survival, cCR, clinical complete response, HPV infection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 10044 Clinic for Radiation Oncology, Primary tumor, CT, computed tomography, 030220 oncology & carcinogenesis, 2730 Oncology, Immunotherapy, medicine.medical_specialty, Disease-free survival, PD-L1, programmed death receptor ligand 1, 610 Medicine & health, Phase 2, Article, OS, overall survival, 03 medical and health sciences, Internal medicine, medicine, 2741 Radiology, Nuclear Medicine and Imaging, Anal cancer, Radiology, Nuclear Medicine and imaging, Radiochemotherapy, MMC, mitomycin C, business.industry, Mitomycin C, Anal Squamous Cell Carcinoma, medicine.disease, Radiation therapy, RCT, radiochemotherapy, ASCC, anal squamous cell carcinoma, 5-FU, 5-fluorouracil, business, MRI, magnetic resonance imaging
الوصف: Highlights • The 3-year disease-free survival of locally-advanced anal carcinoma is about 60%. • Anal carcinoma is considered an immunogenic tumor due to its association with HPV. • The PD-L1 inhibitor durvalumab may synergize with radiochemotherapy. • The RADIANCE trial will test durvalumab with radiochemotherapy in anal carcinoma.
Purpose Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world. The 3-year disease-free survival (DFS) in patients with locally-advanced disease is approximately 60% after primary radiochemotherapy (RCT). There is a strong rationale for combining immunotherapy with RCT in patients with ASCC due to its association with human papilloma virus (HPV) infection. Methods/design RADIANCE is an investigator initiated, prospective, multicenter, randomized phase II trial testing the addition of Durvalumab, a PD-L1 immune checkpoint inhibitor, to standard RCT in 178 patients with locally advanced ASCC (T2 ≥ 4 cm Nany, cT3-4 and/or cN+). In the control arm, patients will be treated with standard mitomycin C (MMC)/5-fluorouracil (5-FU)-based RCT. Intensity-modulated radiotherapy (IMRT) will be applied as follows: PTV_A (primary tumor) T1-T2وصف الملف: 1-s2.0-S2405630820300343-main.pdf - application/pdf
-
6
المؤلفون: Olaf Gefeller, Peter Breinl, Christian Rübe, Attila Salay, Oliver Kölbl, Claus Rödel, Dorota Lubgan, Heinrich Iro, Matthias G. Hautmann, Rainer Fietkau, Markus Hecht, Gerhard G. Grabenbauer, Panagiotis Balermpas, Ulrike Schreck, Patrick Melchior, Benjamin Hofner, Waldemar Krings, Barbara Wollenberg, Birgit Siekmeyer, Rainer Keerl, Stephan Gripp
المصدر: Radiotherapy and Oncology. 144:209-217
مصطلحات موضوعية: medicine.medical_specialty, Paclitaxel, medicine.medical_treatment, Urology, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Leukocytopenia, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Radiology, Nuclear Medicine and imaging, Dose Reduced, Cisplatin, business.industry, Head and neck cancer, Chemoradiotherapy, Hematology, Reference Standards, medicine.disease, Radiation therapy, Oncology, chemistry, Head and Neck Neoplasms, Fluorouracil, 030220 oncology & carcinogenesis, business, medicine.drug
الوصف: Background and purpose This multicenter, phase 3 trial investigates whether the incorporation of concurrent paclitaxel and cisplatin together with a reduced total dose of radiotherapy is superior to standard fluorouracil–cisplatin based CRT. Materials and methods Patients with SCCHN, stage III–IVB, were randomized to receive paclitaxel/cisplatin (PacCis)–CRT (arm A; paclitaxel 20 mg/m2 on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 mg/m2, days 1–4 and 29–32; RT to a total dose of 63.6 Gy) or fluorouracil/cisplatin (CisFU)–CRT (arm B; fluorouracil 600 mg/m2; cisplatin 20 mg/m2, days 1–5 and 29–33; RT: 70.6 Gy). Endpoint was 3-year-disease free survival (3y-DFS). Results A total of 221 patients were enrolled between 2010 and 2015. With a median follow-up of 3.7 years, 3y-DFS in the CisFU arm and PacCis arm was 58.2% and 48.4%, respectively (HR 0.82, 95% CI 0.56–1.21, p = 0.52). The 3y-OS amounted to 64.6% in the CisFU arm, and to 59.2% in the PacCis arm (HR 0.82, 95% CI 0.54–1.24, p = 0.43). In the subgroup of p16-positive oropharyngeal carcinomas, 3y-DFS and 3y-OS was 84.6% vs 83.9% (p = 0.653), and 92.3% vs. 83.5% (p = 0.76) in arm A and B, respectively. Grade 3–4 hematological toxicities were significantly reduced in arm A (anemia, p = 0.01; leukocytopenia, p = 0.003), whereas grade 3 infections were reduced in arm B (p = 0.01). Conclusion Paclitaxel/cisplatin–CRT with a reduced RT-dose is not superior to standard fluorouracil/cisplatin–CRT. Subgroup analyses indicate that a reduced radiation dose seems to be sufficient for p16+ oropharyngeal cancer or non-smokers. Clinical trial information: NCT01126216; EudraCT Number 2005-003484-23.
-
7
المؤلفون: Felix Steger, Matthias G. Hautmann, Franz Josef Putz, Christoph Süß, Barbara Dietl, Michael Behr, Philipp Rechner, Oliver Kölbl, Ulrich Neumaier
المصدر: Strahlentherapie und Onkologie. 196:715-724
مصطلحات موضوعية: Male, medicine.medical_specialty, medicine.medical_treatment, Osteoarthritis, Treatment results, Linear particle accelerator, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Female patient, Humans, Effective treatment, Medicine, Radiology, Nuclear Medicine and imaging, In patient, Aged, Pain Measurement, Retrospective Studies, Aged, 80 and over, business.industry, Treatment options, Middle Aged, Osteoarthritis, Knee, medicine.disease, Radiation therapy, Treatment Outcome, Oncology, Organ Specificity, 030220 oncology & carcinogenesis, Female, Dose Fractionation, Radiation, Radiology, Particle Accelerators, business, Follow-Up Studies
الوصف: Osteoarthritis is a common disease, with a prevalence of symptomatic disease of 8.9%. One treatment option is radiotherapy. Most published samples were treated with an orthovoltage technique or with a telecobalt device. A lot of radiotherapy institutions are nowadays using linear accelerators for treatment of osteoarthritis. There is a discussion on whether the treatment results achieved with a linear accelerator are comparable to those with the orthovoltage technique. The aim of this study is to analyze the results of radiotherapy for osteoarthritis with a linear accelerator and compare the results with reference to different joints. The analysis was performed in patients of two German radiotherapy institutions and included 295 irradiated joints. Pain was documented with the numeric rating scale (NRS). Evaluation of the NRS was done before and directly after each radiation therapy course as well as for the follow-up of 24 months. The median age of the patients was 65 years, with 39.0% male and 61.0% female patients. Most frequently, osteoarthritis of the knee (34.6%) or the finger (15.9%) was treated. We could find a significant response to radiotherapy. Median pain for the whole sample was 7 on the NRS before radiotherapy, 4 after 6 weeks, and 3 after 12 and 24 months. The percentage of patients with 0 or 1 on the NRS was 33.8% 12 months after radiotherapy. All investigated subgroups had a significant reduction of pain. Radiotherapy of osteoarthritis with a linear accelerator is an effective treatment which is very well tolerated. All analyzed subgroups show a good response to radiotherapy for at least 24 months. Orthovoltage therapy seems to be superior to treatment with a linear accelerator in a case-related analysis of the published samples. Further investigations should be performed for a definitive answer to this question.
-
8
المؤلفون: Balint Tamaskovics, Kai Kammers, Kitti Maas, Pirus Ghadjar, Matthias G. Hautmann, Patrick J. Schuler, Edwin Bölke, Thomas K. Hoffmann, Freddy Joel Djiepmo-Njanang, Stefanie Corradini, Christiane Matuschek, Jan Haussmann, Guido Lammering, Wilfried Budach
المصدر: Strahlentherapie und Onkologie. 195:1041-1049
مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.medical_treatment, 030218 nuclear medicine & medical imaging, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Mucositis, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Progression-free survival, Adverse effect, Neoplasm Staging, Randomized Controlled Trials as Topic, Chemotherapy, business.industry, Head and neck cancer, Chemoradiotherapy, medicine.disease, Head and neck squamous-cell carcinoma, Progression-Free Survival, Radiation therapy, Otorhinolaryngologic Neoplasms, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Dose Fractionation, Radiation, business, Follow-Up Studies
الوصف: Adding concurrent chemotherapy (CTx) to definitive radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) improves overall survival. A comparable effect has been reported for hyperfractionated radiotherapy (HFX-RT) alone. Adding concurrent CTx to HFX-RT has been investigated in multiple trials, yet an evident effect on oncological outcomes and toxicity profile has not been established to date. Thus, the aim of the current study was to perform a meta-analysis on the clinical outcome and toxicity of the addition of CTx to HFX-RT. We performed a literature search for randomized controlled trials comparing HFX-RT alone to HFX-RT + concurrent CTx in patients with LA-HNSCC undergoing definite RT. A meta-analysis was performed using the event rates and effect-sizes for overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), distant metastasis-free survival and distant recurrence-free interval (DMFS/DMFI) and locoregional recurrence (LRR) as investigated endpoints. Furthermore, we compared selected acute and late toxicities in the included studies. Statistical analysis was performed using the Microsoft Excel (Microsoft, Redmont, WA, USA) add-in MetaXL 5.3 (EpiGear International, Sunrise Beach, Australia), utilizing the inverse variance heterogeneity model. We identified six studies (n = 1280 patients) randomizing HFX-RT alone and the concurrent addition of CTx. OS was significantly improved in the HFX-RT + CTx group (HR = 0.77, CI95% = 0.66–0.89; p =
-
9
المصدر: Angewandte Chemie. 131:13035-13039
مصطلحات موضوعية: 010405 organic chemistry, 540 Chemie, ddc:540, General Medicine, 010402 general chemistry, 01 natural sciences, 0104 chemical sciences
الوصف: Die Reaktion von tetraedrischen Molybdän‐Komplexen mit unsubstituierten heterodiatomaren Gruppe‐15‐Elementen [Cp2Mo2(CO)4(μ,η2:η2‐PE)] (Cp=C5H5, E=As (1), Sb (2)) mit CuI‐Halogeniden ergab sieben präzedenzlose, neutrale Supramoleküle. In Abhängigkeit von den Mo2PE‐Einheiten und den CuI‐Halogeniden werden die Oligomere [⟨{Cp2Mo2(CO)4}{μ4,η2:η2:η2:η1‐PE}⟩4⟨{CuX}{Cu(μ‐X)}⟩2] (E=As (X=Cl (3), Br (4)); E=Sb (X=Cl (6), Br (7))) oder die 1D‐Koordinationspolymere [{Cp2Mo2(CO)4}{μ4,η2:η2:η1:η1‐PAs}{Cu(μ‐I)}]n (5) und [{Cp2Mo2(CO)4}{μ4,η2:η2:η2:η1‐PSb}2{Cu(μ‐X)}3]n (X=I (8), Br (9)) erhalten. Diese Festkörper‐Aggregate sind die ersten und einzigen Beispiele, die über die metallorganischen heterodiatomaren Mo2PE‐Komplexe 1 und 2 als Verbindungseinheiten verfügen. DFT‐Rechnungen zeigen, dass die Komplexe 1 und 2 eine neue Klasse von gemischten Donorliganden darstellen, die an CuI‐Zentren über das freie P‐Elektronenpaar und die P‐E‐Sigma‐Bindung koordinieren und dabei eine bisher nicht beobachtete Koordinationsform aufweisen.
englische Version unter https://onlinelibrary.wiley.com/doi/10.1002/anie.201907067وصف الملف: application/pdf
-
10
المؤلفون: Felix Steger, Ekrem Ücer, Lars S. Maier, Carsten Jungbauer, Oliver Kölbl, Matthias G. Hautmann, Ute Hubauer, Christoph Süß
المصدر: Strahlentherapie und Onkologie. 195:1086-1093
مصطلحات موضوعية: Pacemaker, Artificial, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Statistics as Topic, Planning target volume, Risk Assessment, 030218 nuclear medicine & medical imaging, Cohort Studies, Contraindications, Procedure, 03 medical and health sciences, Patient safety, 0302 clinical medicine, medicine, Humans, Dosimetry, Radiology, Nuclear Medicine and imaging, Clinical significance, Correlation of Data, Retrospective Studies, Radiotherapy, business.industry, Cumulative dose, Incidence, Dose-Response Relationship, Radiation, Neutron Activation Analysis, Guideline, Defibrillators, Implantable, Equipment Failure Analysis, Radiation therapy, Oncology, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Cohort, Guideline Adherence, Radiology, business
الوصف: Ionizing radiation is able to cause severe damage to cardiac implantable electronic devices (CIED). In Germany, the DEGRO/DGK guideline recommends close monitoring of patients with CIEDs undergoing radiotherapy (RT). Nevertheless, especially in the era of intensity-modulated techniques and predominant use of 6 MV photons, errors of CIEDs are rare events. Therefore, we performed daily CIED controls and hypothesized that no relevant device interaction would occur in our cohort. From 2014 to 2018, we collected data of 51 patients (62 courses) with daily interrogation (n = 1046) of CIED. The dose to the skin above the CIED was measured by semiconductor or ion chamber dosimetry at least once per RT course. In many cases the dose was also calculated. The prescribed dose to the planning target volume (PTV) ranged from 7.5 to 78.0 Gy (IQR 27.8–61.0 Gy). The median measured cumulative dose to the skin above the CIED was 0.17 Gy, whereas the median calculated dose was 1.03 Gy. No error occurred in the group with maximum beam energy >10 MeV. Three events without clinical relevance could be recognized in the group with an intensity-modulated technique at 6 MV. None of the three concerned devices were located directly within the PTV. Errors of CIEDs during RT are rare events. The approach according to the DEGRO/DGK guideline is safe, but also consumes resources. In our cohort it was not compulsory to relocate any CIED. Clinically relevant events are uncommon, so it remains debatable which procedure is necessary. Daily controls could be avoided in some selected cases without compromising patient safety.
إعادة تعيين المنقحات
عرض المنقحات (%%عد%%)
Full Text via ClinicalKey